<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04034706</url>
  </required_header>
  <id_info>
    <org_study_id>1354588</org_study_id>
    <nct_id>NCT04034706</nct_id>
  </id_info>
  <brief_title>Transcriptional and Epigenetic Program of PCOS Women</brief_title>
  <acronym>EPIC</acronym>
  <official_title>Transcriptional and Epigenetic Program of PCOS Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Translational Research Institute for Metabolism and Diabetes, Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Translational Research Institute for Metabolism and Diabetes, Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main goal is to reveal differences in global gene expression in two different adipose
      tissue (AT) depots of females with and without polycystic ovary syndrome (PCOS) and how these
      are influenced by upstream epigenetic markers
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 31, 2020</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Epigenomic and transcriptomic differences in abdominal vs gluteal subcutaneous adipose tissue between females with and without polycystic ovary syndrome</measure>
    <time_frame>6 months after the last participant will be enrolled</time_frame>
    <description>Epigenetic profiles (DNA methylation) and gene expression (RNA-seq) will be performed on whole tissue abdominal fat and gluteofemoral fat biopsies in addition to cultured pre-adipocytes and adipocytes.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>PCOS</condition>
  <arm_group>
    <arm_group_label>PCOS females</arm_group_label>
    <description>Females diagnosed with PCOS with a BMI between 23 and 40 kg/m2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-PCOS control females</arm_group_label>
    <description>Females without PCOS with a BMI between 23 and 40 kg/m2 split into 2 groups- apple shaped and pear shaped.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>DEXA</intervention_name>
    <description>DEXA Scans will be performed to measure body fat and estimate muscle mass using a General Electric Lunar iDXA whole-body scanner.</description>
    <arm_group_label>Non-PCOS control females</arm_group_label>
    <arm_group_label>PCOS females</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Magnetic Resonance (MR) Assessment of the Abdomen</intervention_name>
    <description>Include measures to assess liver lipid content and stiffness and perform volumetric fat quantitation.</description>
    <arm_group_label>Non-PCOS control females</arm_group_label>
    <arm_group_label>PCOS females</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MR assessment of Whole Body Fat</intervention_name>
    <description>Volumetric measurement of fat, muscle and bone</description>
    <arm_group_label>Non-PCOS control females</arm_group_label>
    <arm_group_label>PCOS females</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Adipose tissue biopsy</intervention_name>
    <description>0.5 cm incision of the upper-outer right vastus lateralis, and either a 3-4mm Mercedes Liposuction needle, or a 4-6 mm Bergstrom needle will be inserted to aspirate approximately 7 grams of adipose tissue.</description>
    <arm_group_label>Non-PCOS control females</arm_group_label>
    <arm_group_label>PCOS females</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oral glucose tolerance test</intervention_name>
    <description>Glucose tolerance will be assessed with a 75 g oral glucose tolerance test (OGTT). Subjects will be studied after an overnight fast.</description>
    <arm_group_label>Non-PCOS control females</arm_group_label>
    <arm_group_label>PCOS females</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Recruitment methods utilized may include, but will not be limited to, the following:
        recruitment from within the AdventHealth Translational Research Institute's patient
        population: electronic medical records and database searches (including third party
        recruitment vendors); advertising in multiple media such as print ads, flyers, brochures,
        posters; radio ads; television spots; and internet/social media advertising.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women;

          2. Age 18-45 years inclusive;

          3. BMI 23-40 kg/m2 inclusive;

          4. HbA1C ≤ 6.0% or fasting plasma glucose &lt; 126 mg/dL;

          5. Weight stable (± 3 kg) during the 3 months prior to enrollment;

          6. Women must be &gt; 9 months post-partum;

          7. For PCOS: A documented history of PCOS from their physician according to the Androgen
             Excess (AE)-PCOS criteria: (defined by the presence of hyperandrogenism (clinical
             and/or biochemical), ovarian dysfunction (oligo-anovulation and/or polycystic
             ovaries), and the exclusion of related disorders (eg. hypoadrenalism, ovarian tumors)

          8. Regular menstrual cycle for females without PCOS

          9. Able to provide written, informed consent.

        Exclusion Criteria:

          1. Postmenopausal women

          2. Women with hysterectomy

          3. Pregnancy, lactation or &lt; 9 months postpartum from the scheduled date of screening.

          4. Fasting plasma glucose &gt; 126 mg/dL, or HbA1c &gt; 6% or diagnosis with Type 2 Diabetes
             (T2D) or Type 1 Diabetes (T1D)

          5. History or presence of cardiovascular disease (unstable angina, myocardial infarction
             or coronary revascularization within 6 months, clinically significant abnormalities on
             EKG), presence of cardiac pacemaker, implanted cardiac defibrillator.

          6. Liver disease (AST or ALT &gt;2.5 times the upper limit of normal)

          7. Kidney disease (creatinine &gt;1.6 mg/dl or estimated GFR &lt;60 ml/min)

          8. Dyslipidemia, including triglycerides &gt;500 mg/dl, LDL &gt;200 mg/dl

          9. Anemia (hemoglobin &lt;11 g/dl)

         10. Thyroid dysfunction (suppressed thyroid-stimulating hormone, elevated TSH &lt;10 µIU/ml
             if symptomatic or elevated TSH &gt;10 µIU/ml if asymptomatic)

         11. Uncontrolled hypertension (BP &gt;160 mmHg systolic or &gt;100 mmHg diastolic)

         12. Elevated hsCRP or known active infection

         13. History of cancer within the last 5 years (skin cancers, with the exception of
             melanoma, may be acceptable)

         14. History of drug or alcohol abuse (&gt; 3 drinks per day) within the last 5 years. Current
             drug use may be determined by plasma or urine drug screens.

         15. psychiatric disease prohibiting adherence to study protocol.

         16. History of organ transplant.

         17. Known history of HIV, active Hepatitis A, B or C or tuberculosis.

         18. History of bariatric surgery.

         19. Current smokers (smoking within the past 3 months).

         20. Current use of beta-adrenergic blocking agents.

         21. Use of oral or injectable anti-hyperglycemic agents: metformin, sulfonylureas, DPP IV
             inhibitors, SGLT-2 inhibitors, thiazolidinediones, acarbose, GLP-1 analogs and insulin
             unless willing to undertake a washout period of 15 days for metformin and GLP-1
             analogs and undergo subsequent laboratory screening tests.

         22. Gonadotropin Releasing Hormone (GnRH) and/or Antiandrogen use within the last 2
             months.

         23. Use of any medications known to influence fat and/or energy metabolism (eg growth
             hormone therapy, glucocorticoids [steroids], etc.)

         24. Initiation or change in hormone replacement therapy within the past 3 months
             (including, but not limited to thyroid hormone, estrogen replacement therapy or In
             Vitro Fertilization therapy).

         25. Current treatment with blood thinners or antiplatelet medications that cannot be
             safely stopped for biopsy and testing procedures.

         26. Not able or willing to have DXA scans or are above the acceptable weight limit (450
             lbs) of the DXA scanner.

         27. Presence of any condition that, in the opinion of the Investigators, compromises
             participant safety or data integrity or the participant's ability to complete study
             visits.

         28. Not able to participate in MRI assessments due to:

               1. Metal implants (pacemaker, non-removable body piercings, aneurysm clips) based on
                  Investigator's judgment at screening

               2. Physical limitations or equipment tolerances (e.g., MRI bore size) based on
                  Investigator's judgment at screening

               3. Inability to tolerate MRI imaging without sedation or claustrophobia
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Principal Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruitment Dept</last_name>
    <phone>407-303-7100</phone>
    <email>fh.tri@flhosp.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>AdventHealth Translational Research Institute</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Recruitment Dept</last_name>
      <phone>407-303-7100</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.adventhealth.com/research/translational-research-institute-metabolism-and-diabetes</url>
    <description>Website for AdventHealth Translational Research Institute</description>
  </link>
  <reference>
    <citation>Abbott DH, Barnett DK, Bruns CM, Dumesic DA. Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome? Hum Reprod Update. 2005 Jul-Aug;11(4):357-74. Review.</citation>
    <PMID>15941725</PMID>
  </reference>
  <reference>
    <citation>Abbott DH, Dumesic DA, Eisner JR, Colman RJ, Kemnitz JW. Insights into the development of polycystic ovary syndrome (PCOS) from studies of prenatally androgenized female rhesus monkeys. Trends Endocrinol Metab. 1998 Feb;9(2):62-7.</citation>
    <PMID>18406243</PMID>
  </reference>
  <reference>
    <citation>Azziz R, Carmina E, Chen Z, Dunaif A, Laven JS, Legro RS, Lizneva D, Natterson-Horowtiz B, Teede HJ, Yildiz BO. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016 Aug 11;2:16057. doi: 10.1038/nrdp.2016.57. Review.</citation>
    <PMID>27510637</PMID>
  </reference>
  <reference>
    <citation>Barber TM, Golding SJ, Alvey C, Wass JA, Karpe F, Franks S, McCarthy MI. Global adiposity rather than abnormal regional fat distribution characterizes women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008 Mar;93(3):999-1004. Epub 2007 Dec 18.</citation>
    <PMID>18089693</PMID>
  </reference>
  <reference>
    <citation>Björntorp P. Adipose tissue distribution and function. Int J Obes. 1991 Sep;15 Suppl 2:67-81.</citation>
    <PMID>1794941</PMID>
  </reference>
  <reference>
    <citation>Bos G, Snijder MB, Nijpels G, Dekker JM, Stehouwer CD, Bouter LM, Heine RJ, Jansen H. Opposite contributions of trunk and leg fat mass with plasma lipase activities: the Hoorn study. Obes Res. 2005 Oct;13(10):1817-23.</citation>
    <PMID>16286530</PMID>
  </reference>
  <reference>
    <citation>Ciaraldi TP, Aroda V, Mudaliar S, Chang RJ, Henry RR. Polycystic ovary syndrome is associated with tissue-specific differences in insulin resistance. J Clin Endocrinol Metab. 2009 Jan;94(1):157-63. doi: 10.1210/jc.2008-1492. Epub 2008 Oct 14.</citation>
    <PMID>18854391</PMID>
  </reference>
  <reference>
    <citation>de Koning L, Merchant AT, Pogue J, Anand SS. Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies. Eur Heart J. 2007 Apr;28(7):850-6. Epub 2007 Apr 2. Review.</citation>
    <PMID>17403720</PMID>
  </reference>
  <reference>
    <citation>Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012 Dec;33(6):981-1030. doi: 10.1210/er.2011-1034. Epub 2012 Oct 12. Review.</citation>
    <PMID>23065822</PMID>
  </reference>
  <reference>
    <citation>Divoux A, Karastergiou K, Xie H, Guo W, Perera RJ, Fried SK, Smith SR. Identification of a novel lncRNA in gluteal adipose tissue and evidence for its positive effect on preadipocyte differentiation. Obesity (Silver Spring). 2014 Aug;22(8):1781-5. doi: 10.1002/oby.20793. Epub 2014 May 23.</citation>
    <PMID>24862299</PMID>
  </reference>
  <reference>
    <citation>Elbers JM, Asscheman H, Seidell JC, Gooren LJ. Effects of sex steroid hormones on regional fat depots as assessed by magnetic resonance imaging in transsexuals. Am J Physiol. 1999 Feb;276(2):E317-25. doi: 10.1152/ajpendo.1999.276.2.E317.</citation>
    <PMID>9950792</PMID>
  </reference>
  <reference>
    <citation>Elbers JM, Asscheman H, Seidell JC, Megens JA, Gooren LJ. Long-term testosterone administration increases visceral fat in female to male transsexuals. J Clin Endocrinol Metab. 1997 Jul;82(7):2044-7.</citation>
    <PMID>9215270</PMID>
  </reference>
  <reference>
    <citation>Frayn KN. Adipose tissue as a buffer for daily lipid flux. Diabetologia. 2002 Sep;45(9):1201-10. Epub 2002 Jul 24. Review.</citation>
    <PMID>12242452</PMID>
  </reference>
  <reference>
    <citation>Guo Z, Johnson CM, Jensen MD. Regional lipolytic responses to isoproterenol in women. Am J Physiol. 1997 Jul;273(1 Pt 1):E108-12.</citation>
    <PMID>9252486</PMID>
  </reference>
  <reference>
    <citation>Horowitz JF, Klein S. Whole body and abdominal lipolytic sensitivity to epinephrine is suppressed in upper body obese women. Am J Physiol Endocrinol Metab. 2000 Jun;278(6):E1144-52.</citation>
    <PMID>10827018</PMID>
  </reference>
  <reference>
    <citation>Jason J. Polycystic ovary syndrome in the United States: clinical visit rates, characteristics, and associated health care costs. Arch Intern Med. 2011 Jul 11;171(13):1209-11. doi: 10.1001/archinternmed.2011.288.</citation>
    <PMID>21747019</PMID>
  </reference>
  <reference>
    <citation>Karastergiou K, Fried SK, Xie H, Lee MJ, Divoux A, Rosencrantz MA, Chang RJ, Smith SR. Distinct developmental signatures of human abdominal and gluteal subcutaneous adipose tissue depots. J Clin Endocrinol Metab. 2013 Jan;98(1):362-71. doi: 10.1210/jc.2012-2953. Epub 2012 Nov 12.</citation>
    <PMID>23150689</PMID>
  </reference>
  <reference>
    <citation>Kirchengast S, Huber J. Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Hum Reprod. 2001 Jun;16(6):1255-60.</citation>
    <PMID>11387301</PMID>
  </reference>
  <reference>
    <citation>Kokosar M, Benrick A, Perfilyev A, Fornes R, Nilsson E, Maliqueo M, Behre CJ, Sazonova A, Ohlsson C, Ling C, Stener-Victorin E. Epigenetic and Transcriptional Alterations in Human Adipose Tissue of Polycystic Ovary Syndrome. Sci Rep. 2016 Mar 15;6:22883. doi: 10.1038/srep22883. Erratum in: Sci Rep. 2016 May 09;6:25321.</citation>
    <PMID>26975253</PMID>
  </reference>
  <reference>
    <citation>Lavebratt C, Almgren M, Ekström TJ. Epigenetic regulation in obesity. Int J Obes (Lond). 2012 Jun;36(6):757-65. doi: 10.1038/ijo.2011.178. Epub 2011 Sep 13. Review.</citation>
    <PMID>21912396</PMID>
  </reference>
  <reference>
    <citation>Mannerås-Holm L, Leonhardt H, Kullberg J, Jennische E, Odén A, Holm G, Hellström M, Lönn L, Olivecrona G, Stener-Victorin E, Lönn M. Adipose tissue has aberrant morphology and function in PCOS: enlarged adipocytes and low serum adiponectin, but not circulating sex steroids, are strongly associated with insulin resistance. J Clin Endocrinol Metab. 2011 Feb;96(2):E304-11. doi: 10.1210/jc.2010-1290. Epub 2010 Nov 17.</citation>
    <PMID>21084397</PMID>
  </reference>
  <reference>
    <citation>Manolopoulos KN, Karpe F, Frayn KN. Gluteofemoral body fat as a determinant of metabolic health. Int J Obes (Lond). 2010 Jun;34(6):949-59. doi: 10.1038/ijo.2009.286. Epub 2010 Jan 12. Review.</citation>
    <PMID>20065965</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>July 24, 2019</study_first_submitted>
  <study_first_submitted_qc>July 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2019</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

